Citations

Showing 10 of 108083 citations.

Effects of alteplase for acute stroke according to criteria defining the European Union and United States marketing authorizations: Individual-patient-data meta-analysis of randomized trials
Hacke, Werner , Lyden, Patrick D. , Emberson, Jonathan , Blackwell, Lisa, Albers, Gregory W. , Bluhmki, Erich , Brott, Thomas, Cohen, Geoffrey, Davis, Stephen M. , Grotta, James C. , Howard, George , Kaste, Markku , Koga, Masatoshi , Lansberg, Maarten G. , Lindley, Richard I. , Olivot, Jean‐Marc , Toni, Danilo , Wahlgren, Nils , Wardlaw, Joanna M. , Whiteley, William , Zoppo, Gregory del, Group, on behalf of the Stroke Thrombolysis Trialists’ Collaborators, Lindley, Richard I , Sandercock, Peter Ag , Wardlaw, Joanna Marguerite , Baigent, Colin , Cohen, Geoff, Donnan, Geoffrey A. , Kummer, Rüdiger von , Parsons, Mark W , Sandercock, Peter , Toyoda, Ḱazunori , Lees, Kennedy R. , Group, on behalf of the Stroke Thrombolysis Trialists’ Collaborators, Howard, George , Whiteley, William N , Grotta, James C

Mayo Clinic

International Journal of Stroke | November 24, 2017 | Volume: 13 | Issue: 2 | Pages: 175-189

10.1177/1747493017744464 | PMID 29171359 Get It

Background The recommended maximum age and time window for intravenous alteplase treatment of acute ischemic stroke differs between the Europe Union and United States. Aims We compared the effects of alteplase in cohorts defined by the current Europe Union or United States marketing approval labels, and by hypothetical revisions of the labels that would remove the Europe Union upper age limit or extend the United States treatment time window to 4.5 h. Methods We assessed outcomes in an individual-patient-data meta-analysis of eight randomized trials of intravenous alteplase (0.9 mg/kg) versus control for acute ischemic stroke. Outcomes included: excellent outcome (modified Rankin score 0–1) at 3–6 months, the distribution of modified Rankin score, symptomatic intracerebral hemorrhage, and 90-day mortality. Results Alteplase increased the odds of modified Rankin score 0–1 among 2449/6136 (40%) patients who met the current European Union label and 3491 (57%) patients who met the age-revised label (odds ratio 1.42, 95% CI 1.21−1.68 and 1.43, 1.23−1.65, respectively), but not in those outside the age-revised label (1.06, 0.90−1.26). By 90 days, there was no increased mortality in the current and age-revised cohorts (hazard ratios 0.98, 95% CI 0.76−1.25 and 1.01, 0.86–1.19, respectively) but mortality remained higher outside the age-revised label (1.19, 0.99–1.42). Similarly, alteplase increased the odds of modified Rankin score 0-1 among 1174/6136 (19%) patients who met the current US approval and 3326 (54%) who met a 4.5-h revised approval (odds ratio 1.55, 1.19−2.01 and 1.37, 1.17−1.59, respectively), but not for those outside the 4.5-h revised approval (1.14, 0.97−1.34). By 90 days, no increased mortality remained for the current and 4.5-h revised label cohorts (hazard ratios 0.99, 0.77−1.26 and 1.02, 0.87–1.20, respectively) but mortality remained higher outside the 4.5-h revised approval (1.17, 0.98–1.41). Conclusions An age-revised European Union label or 4.5-h-revised United States label would each increase the number of patients deriving net benefit from alteplase by 90 days after acute ischemic stroke, without excess mortality.
Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision‐making in otherwise low or intermediate‐1 risk patients with myelofibrosis
Tefferi, Ayalew , Hanson, Curtis A. , Gangat, Naseema , Pardanani, Animesh , Lasho, Terra L. , Gangat, Naseema , Ketterling, Rhett P.

Mayo Clinic

British Journal of Haematology | November 24, 2017 | Volume: 183 | Issue: 4 | Pages: 678-681

10.1111/bjh.15010 | PMID 29171022 Get It

Phase-contrast imaging with a compact x-ray light source: system design
Sung, Yongjin , Gupta, Rajiv , Nelson, Brandon , Graves, W. , McCollough, Cynthia H , Leng, Shuai , Leng, Shuai , McCollough, Cynthia H.

Mayo Clinic

Journal of Medical Imaging | November 23, 2017 | Volume: 4 | Issue: 04 | Pages: 1

10.1117/1.jmi.4.4.043503 | PMID 29201939 Get It

Joint associations of a polygenic risk score and environmental risk factors for breast cancer in the Breast Cancer Association Consortium
Song, Minsun , Brook, Mark N. , Michailidou, Kyriaki , Bolla, Manjeet K. , Wang, Qin , Wilcox, Amber N, Hopper, John L. , Keeman, Renske , Fasching, Peter A. , Beckmann, Matthias W. , Gago-Domínguez, Manuela , Castelao, Jose E. , Guénel, Pascal , Truong, Thérèse , Bojesen, Stig E. , Flyger, Henrik, Brenner, Hermann , Brauch, Hiltrud , Brüning, Thomas , Mannermaa, Arto, Kosma, Veli-Matti, Lambrechts, Diether , Keupers, Machteld , Couch, Fergus J. , Vachon, Celine M. , MacInnis, Robert J. , Figueroa, Jonine D. , Brinton, Louise A. , Brand, Judith S. , Gabrielson, Marike , Humphreys, Keith , Orr, Nick , Swerdlow, Anthony J. , Easton, Douglas F. , Chatterjee, Nilanjan , Chang‐Claude, Jenny , García‐Closas, Montserrat , Lambrechts, Diether , Wilcox, Amber N , Vachon, Celine, Lambrechts, Diether , Swerdlow, Anthony J , Maclnnis, Robert , Lambrechts, Diether , Brenner, Hermann , Gago-Dominguez, Manuela , Guénel, Pascal , García-Closas, Montserrat , Michailidou, Kyriaki , Figueroa, Jonine D , Gabrielson, Marike , Rudolph, Anja , Milne, Roger L. , Mavaddat, Nasim , Dennis, Joe , Hurson, Amber N. , Southey, Melissa C. , Arndt, Volker , Mannermaa, Arto, Couch, Fergus J. , Vachon, Celine M. , Giles, Graham G. , Czene, Kamila , Cox, Angela , Cross, Simon S. , Dunning, Alison M. , Hall, Per N , Pharoah, Paul D.P. , Schmidt, Marjanka K. , Bojesen, Stig E , Truong, Therese , Brauch, Hiltrud , Orr, Nick

Mayo Clinic

International Journal of Epidemiology | November 23, 2017 | Volume: 47 | Issue: 2 | Pages: 526-536

10.1093/ije/dyx242 | PMID 29315403 Get It

Cost‐Effectiveness of a Care Transitions Program in a Multimorbid Older Adult Cohort
Hanson, Gregory J. , Moriarty, James P. , Ransom, Jeanine E. , Naessens, James M. , Takahashi, Paul Y. , Borah, Bijan J. , Takahashi, Paul

Mayo Clinic

Journal of the American Geriatrics Society | November 23, 2017 | Volume: 66 | Issue: 2 | Pages: 297-301

10.1111/jgs.15203 | PMID 29168880 Get It

Background/Objectives Facing penalties for preventable 30‐day hospital readmissions, many provider groups have implemented programs to remedy this problem, but the cost efficacy and value of such programs are not well delineated. The objective was to compare total cost of care over 30 days of individuals enrolled in the Mayo Clinic Care Transitions ( MCCT ) program and individuals not enrolled. Design Retrospective cohort study using secondary data analysis of a previously published cohort study. Setting Mayo Clinic, Rochester, Minnesota. Participants MCCT participants (n = 363) and individuals in a propensity‐matched referent cohort (n = 365). Intervention MCCT program enrollment. Measurements The primary outcome was total cost of care over 30 days after hospital discharge. A 2‐part modeling strategy was used to analyze 30‐day costs: whether individuals had non‐zero costs during the 30 days after discharge and a generalized linear model for individuals who incurred costs. Potential heterogeneous effects of the MCCT program were examined according to decile of 30‐day costs using quantile regression. Results Mean age was 83 in both groups. Adjusted mean 30‐day cost after hospitalization was $3,363 (95% confidence interval ( CI ) = $2,512−4,213) in the MCCT group and $4,161 (95% CI = $3,096−5,226) in the control group ( P = .25). Cost savings of $2,744 ( P = .008) at the eighth decile and $3,388 ( P = .20) at the ninth decile were demonstrated. Thus, the only statistically significant differences were in the post hoc subgroup analysis in the highest‐cost subgroups. Conclusion We did not find a difference in overall mean costs between the MCCT group and the control group, although intervention participants in the upper deciles of costs appeared to experience lower costs than controls. A larger study cohort might better determine the value of the intervention.
Clinical and pathological phenotype of genetic causes of focal segmental glomerulosclerosis in adults
Lepori, Nicola , Zand, Ladan , Sethi, Sanjeev , Fernández‐Juárez, Gema , Fervenza, Fernando C. , Fernández-Juárez, Gema

Mayo Clinic

Clinical Kidney Journal | November 23, 2017 | Volume: 11 | Issue: 2 | Pages: 179-190

10.1093/ckj/sfx143 | PMID 29644057 Get It

17α‐estradiol acts through hypothalamic pro‐opiomelanocortin expressing neurons to reduce feeding behavior
Steyn, Frederik J. , Ngo, Shyuan T. , Chen, Vicky Ping , Bailey‐Downs, Lora C., Xie, Teresa, Ghadami, Martin, Brimijoin, Stephen , Freeman, Willard M. , Rubinstein, Marcelo , Low, Malcolm J. , Steyn, F J , Freeman, Willard M , Stout, Michael B

Mayo Clinic

Aging Cell | November 23, 2017 | Volume: 17 | Issue: 1 | Pages: No page available

10.1111/acel.12703 | PMID 29168299 Get It

SummaryWeight loss is an effective intervention for diminishing disease burden in obese older adults. Pharmacological interventions that reduce food intake and thereby promote weight loss may offer effective strategies to reduce age‐related disease. We previously reported that 17α‐estradiol (17α‐E2) administration elicits beneficial effects on metabolism and inflammation in old male mice. These observations were associated with reduced calorie intake. Here, we demonstrate that 17α‐E2 acts through pro‐opiomelanocortin (Pomc) expression in the arcuate nucleus (ARC) to reduce food intake and body mass in mouse models of obesity. These results confirm that 17α‐E2 modulates appetite through selective interactions within hypothalamic anorexigenic pathways. Interestingly, some peripheral markers of metabolic homeostasis were also improved in animals with near complete loss of ARC Pomc transcription. This suggests that 17α‐E2 might have central and peripheral actions that can beneficially affect metabolism cooperatively or independently.
Newer Insights into the Management of Interstitial Lung Disease in Systemic Sclerosis
Mango, Robert L, Ryu, Jay H, Ryu, Jay H. , Ryu, Jay H , Mango, Robert L, Ryu, Jay H, Makol, Ashima

Mayo Clinic

Indian Journal of Rheumatology | November 23, 2017 | Volume: 12 | Issue: 2S | Pages: No page available

10.4103/0973-3698.219084 Get It

Type 2 Diabetes is Cardiovascular Disease
Dhatariya, Ketan

Mayo Clinic

Journal of the Royal Society of Medicine | November 23, 2017 | Volume: 96 | Issue: 8 | Pages: 371-372

10.1177/014107680309600801 | PMID 12893849 Get It

Adolescence and risk of preterm birth in multifetal gestations
Alrahmani, Layan , Abdelsattar, Zaid M. , Adekola, Henry , Gonik, Bernard , Awonuga, Awoniyi O. , Alrahmani, Layan

Mayo Clinic

The Journal of Maternal-Fetal & Neonatal Medicine | November 22, 2017 | Volume: 32 | Issue: 8 | Pages: 1321-1324

10.1080/14767058.2017.1404981 | PMID 29166804 Get It